CIPLA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,479 INR | -1.37% |
|
-6.08% | +18.68% |
| 06-25 | US FDA Classifies Inspection of Cipla's Patalganga Manufacturing Facility as Voluntary Action Indicated | MT |
| 06-24 | INDIA STOCKS-Financials weigh on Indian shares; small-, mid-caps fall | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products.
Net sales by source of income break down between sale of products (96.9%) and services (3.1%).
Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).
Sector
Pharmaceuticals
Calendar
2024-08-01
- Détachement de for final dividend
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
34
Last Close Price
1,479
INR
Average target price
1,499
INR
Spread / Average Target
+1.32%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.68% | 14.52B | |
| +20.78% | 43.29B | |
| +27.64% | 22.38B | |
| +19.25% | 15.51B | |
| +54.64% | 12.93B | |
| -0.05% | 6.79B | |
| -11.39% | 6.56B | |
| +18.33% | 5.87B | |
| -8.87% | 5.73B | |
| +6.11% | 4.68B |
- Stock Market
- Equities
- CIPLA Stock
- News Cipla Limited
- Jefferies Adjusts Cipla’s Price Target to INR1,400 From INR1,250, Keeps at Hold
